semaglutide fda approval mash Novo's Wegovy becomes first GLP-1 drug approved for Diabetes Dialogue: FDA Approves Semaglutide

It slows digestion, keeps you full longer, and turns down appetite signals

Clinical studies show that patients typically lose 10-20% of their body weight over several months with GLP-1 therapy

Early symptoms of NAION related vision loss can include: Loss of vision upon waking Dark area or shadow in vision Blurred vision Color vision loss Loss of contrast Light sensitivity Periocular eye pain Headache Ozempic, Mounjaro and Other Drugs Popular for Weight Loss Novo Nordisk research published in a popular medical journal The Lancet shows that the active ingredient in Ozempic may help a person lose about 15% of their body weight

Unfortunately, factors like stress, poor diet, aging, and pollution can deplete your natural Glutathione levels, leaving your body more vulnerable to oxidative stress and premature aging

& Wang, P.-H

A 2019 study published in Diabetes Care (Frias et al.) examined the combination of semaglutide with an SGLT2 inhibitor and found additive reductions in both HbA1c and body weight compared to either medication used alone, with no significant increase in adverse events beyond what was expected from each medication individually